BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 17102121)

  • 1. Expression and processing of the neuroendocrine protein secretogranin II in benign and malignant pheochromocytomas.
    Guillemot J; Barbier L; Thouennon E; Vallet-Erdtmann V; Montero-Hadjadje M; Lefebvre H; Klein M; Muresan M; Plouin PF; Seidah N; Vaudry H; Anouar Y; Yon L
    Ann N Y Acad Sci; 2006 Aug; 1073():527-32. PubMed ID: 17102121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential expression and processing of secretogranin II in relation to the status of pheochromocytoma: implications for the production of the tumoral marker EM66.
    Guillemot J; Thouënnon E; Guérin M; Vallet-Erdtmann V; Ravni A; Montéro-Hadjadje M; Lefebvre H; Klein M; Muresan M; Seidah NG; Anouar Y; Yon L
    J Mol Endocrinol; 2012 Apr; 48(2):115-27. PubMed ID: 22217803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of novel tools for the diagnosis and prognosis of pheochromocytoma using peptide marker immunoassay and gene expression profiling approaches.
    Anouar Y; Yon L; Guillemot J; Thouennon E; Barbier L; Gimenez-Roqueplo AP; Bertherat J; Lefebvre H; Klein M; Muresan M; Grouzmann E; Plouin PF; Vaudry H; Elkahloun AG
    Ann N Y Acad Sci; 2006 Aug; 1073():533-40. PubMed ID: 17102122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of the secretogranin II-derived peptide EM66 in pheochromocytomas as a potential marker for discriminating benign versus malignant tumors.
    Yon L; Guillemot J; Montero-Hadjadje M; Grumolato L; Leprince J; Lefebvre H; Contesse V; Plouin PF; Vaudry H; Anouar Y
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2579-85. PubMed ID: 12788858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Granins and their derived peptides in normal and tumoral chromaffin tissue: Implications for the diagnosis and prognosis of pheochromocytoma.
    Guérin M; Guillemot J; Thouënnon E; Pierre A; El-Yamani FZ; Montero-Hadjadje M; Dubessy C; Magoul R; Lihrmann I; Anouar Y; Yon L
    Regul Pept; 2010 Nov; 165(1):21-9. PubMed ID: 20600356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stathmin as a marker for malignancy in pheochromocytomas.
    Björklund P; Cupisti K; Fryknäs M; Isaksson A; Willenberg HS; Akerström G; Hellman P; Westin G
    Exp Clin Endocrinol Diabetes; 2010 Jan; 118(1):27-30. PubMed ID: 19449284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of chromogranins A, B, and C (secretogranin II) in human adrenal medulla and in benign and malignant pheochromocytomas An immunohistochemical study with region-specific antibodies.
    Portela-Gomes GM; Stridsberg M; Grimelius L; Falkmer UG; Falkmer S
    APMIS; 2004 Oct; 112(10):663-73. PubMed ID: 15601318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Candidate genes associated with malignant pheochromocytomas by genome-wide expression profiling.
    Suh I; Shibru D; Eisenhofer G; Pacak K; Duh QY; Clark OH; Kebebew E
    Ann Surg; 2009 Dec; 250(6):983-90. PubMed ID: 19661783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating EM66 is a highly sensitive marker for the diagnosis and follow-up of pheochromocytoma.
    Guillemot J; Anouar Y; Montero-Hadjadje M; Grouzmann E; Grumolato L; Roshmaninho-Salgado J; Turquier V; Duparc C; Lefebvre H; Plouin PF; Klein M; Muresan M; Chow BK; Vaudry H; Yon L
    Int J Cancer; 2006 Apr; 118(8):2003-12. PubMed ID: 16287097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic management of benign and malignant pheochromocytoma.
    Scholz T; Schulz C; Klose S; Lehnert H
    Exp Clin Endocrinol Diabetes; 2007 Mar; 115(3):155-9. PubMed ID: 17427102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microarray analysis reveals differential expression of benign and malignant pheochromocytoma.
    Waldmann J; Fendrich V; Holler J; Buchholz M; Heinmöller E; Langer P; Ramaswamy A; Samans B; Walz MK; Rothmund M; Bartsch DK; Slater EP
    Endocr Relat Cancer; 2010 Sep; 17(3):743-56. PubMed ID: 20562231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of potential gene markers and insights into the pathophysiology of pheochromocytoma malignancy.
    Thouënnon E; Elkahloun AG; Guillemot J; Gimenez-Roqueplo AP; Bertherat J; Pierre A; Ghzili H; Grumolato L; Muresan M; Klein M; Lefebvre H; Ouafik L; Vaudry H; Plouin PF; Yon L; Anouar Y
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4865-72. PubMed ID: 17878247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The significance of Ki-67 antigen expression in the distinction between benign and malignant pheochromocytomas].
    Feng C; Li HZ; Yan WG; Gao JG; Xu WF; Luo YF; Cao JL
    Zhonghua Wai Ke Za Zhi; 2007 Dec; 45(24):1697-700. PubMed ID: 18476530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteolytic processing and differential distribution of secretogranin-II in goldfish.
    Zhao E; Basak A; Crump K; Trudeau VL
    Gen Comp Endocrinol; 2006 Apr; 146(2):100-7. PubMed ID: 16376889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a novel secretogranin II-derived peptide (SgII(187-252)) in adult and fetal human adrenal glands using antibodies raised against the human recombinant peptide.
    Anouar Y; Desmoucelles C; Yon L; Leprince J; Breault L; Gallo-Payet N; Vaudry H
    J Clin Endocrinol Metab; 1998 Aug; 83(8):2944-51. PubMed ID: 9709974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential Expression of Secretogranins II and III in Canine Adrenal Chromaffin Cells and Pheochromocytomas.
    Gomi H; Nagumo T; Asano K; Konosu M; Yasui T; Torii S; Hosaka M
    J Histochem Cytochem; 2022 May; 70(5):335-356. PubMed ID: 35400231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morphometric analysis of benign and malignant adrenal pheochromocytomas.
    Hoffman K; Gil J; Barba J; Liu Z; Pertsemlidis D; Kaneko M; Unger P
    Arch Pathol Lab Med; 1993 Mar; 117(3):244-7. PubMed ID: 8442669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methylation of the p16INK4A promoter is associated with malignant behavior in abdominal extra-adrenal paragangliomas but not pheochromocytomas.
    Kiss NB; Geli J; Lundberg F; Avci C; Velazquez-Fernandez D; Hashemi J; Weber G; Höög A; Ekström TJ; Bäckdahl M; Larsson C
    Endocr Relat Cancer; 2008 Jun; 15(2):609-21. PubMed ID: 18509008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Malignancy in pheochromocytomas.
    Salmenkivi K; Heikkilä P; Haglund C; Arola J
    APMIS; 2004 Sep; 112(9):551-9. PubMed ID: 15601303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis.
    Strong VE; Kennedy T; Al-Ahmadie H; Tang L; Coleman J; Fong Y; Brennan M; Ghossein RA
    Surgery; 2008 Jun; 143(6):759-68. PubMed ID: 18549892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.